ArticleNanotechnology2013
Gold nanorod vaccine for respiratory syncytial virus.
Article in Nanotechnology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 72 citations in OpenAlex.
- Computational design and investigation of the monomeric spike SARS-CoV-2-ferritin nanocage vaccine stability and interactions.Frontiers in molecular biosciences · 2024Article
- Nanoparticles and Antiviral Vaccines.Vaccines · 2023Review
- Nanoparticle-Based Delivery Systems for Vaccines.Vaccines · 2022Review
- Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines.Biomaterials advances · 2022Review
- Efficacy and Immune Response Elicited by Gold Nanoparticle- Based Nanovaccines against Infectious Diseases.Vaccines · 2022Review
- Recent advances on therapeutic potentials of gold and silver nanobiomaterials for human viral diseases.Current research in chemical biology · 2022Review
- Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines.Vaccines · 2021Review
- Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses.PPAR research · 2021Review
- Nanoparticle vaccines against respiratory syncytial virus.Future virology · 2020Review
- Nanosensors based on LSPR are able to serologically differentiate dengue from Zika infections.Scientific reports · 2020Article
- Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases.Expert review of vaccines · 2020Review
- In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Surface chemistry of gold nanoparticles for health-related applications.Chemical science · 2020Review
- A supramolecular protein chaperone for vaccine delivery.Theranostics · 2020Article
- Magnetic-Plasmonic Heterodimer Nanoparticles: Designing Contemporarily Features for Emerging Biomedical Diagnosis and Treatments.Nanomaterials (Basel, Switzerland) · 2019Review
- Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications.Chemical Society reviews · 2018Review
- Functional ferritin nanoparticles for biomedical applications.Frontiers of chemical science and engineering · 2017Article
- Tolerogenic Nanoparticles to Treat Islet Autoimmunity.Current diabetes reports · 2017Review
- Applications of Gold Nanoparticles in Nanomedicine: Recent Advances in Vaccines.Molecules (Basel, Switzerland) · 2017Review
- Immunological properties of gold nanoparticles.Chemical science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Respiratory syncytial virus (RSV) is a major cause of pneumonia and wheezing in infants and the elderly, but to date there is no licensed vaccine. We developed a gold nanorod construct that displayed the major protective antigen of the virus, the fusion protein (F). Nanorods conjugated to RSV F were formulated as a candidate vaccine preparation by covalent attachment of viral protein using a layer-by-layer approach. In vitro studies using ELISA, electron microscopy and circular dichroism revealed that conformation-dependent epitopes were maintained during conjugation, and transmission electron microscopy studies showed that a dispersed population of particles could be achieved. Human dendritic cells treated with the vaccine induced immune responses in primary human T cells. These results suggest that this vaccine approach may be a potent method for immunizing against viruses such as RSV with surface glycoproteins that are targets for the human immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.